Drug Trial Radar · NCT06643481
A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
Last checked: Nov 19, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
251
Actual
Start
Oct 17, 2024
Primary completion
Jun 23, 2026
Study completion Jul 10, 2028
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Oct 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early-stage ALS (within 2 years of ALS symptoms onset). The study comprises a core double-blind (DB) 40-week treatment period followed by an open label extension (OLE).
Conditions
- Amyotrophic Lateral Sclerosis (ALS)
Interventions
VHB937Biological
VHB937 solution for infusion
PlaceboOther
Solution for infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- The composite of PAV-free survival and change in ALSFRS-R. Analysis method: Combined Assessment of Function and Survival (CAFS)Time frame: Baseline to DB Week 40
Locations
74 sites in 17 countries. Site status is shown where the registry gives one.
University of California San Diego
La Jolla, California
Loma Linda University Health
Loma Linda, California
Keck Medical Center USC
Los Angeles, California
UC San Francisco Medical Center
San Francisco, California
University of Miami
Miami, Florida
Orlando Health Clinical Trials
Orlando, Florida
Emory University School of Medicine
Atlanta, Georgia
University Of Kansas Medical Center
Kansas City, Kansas
Massachusetts General Hospital
Boston, Massachusetts
University of Nebraska Medical Center
Omaha, Nebraska
Lange Neurology PC
New York, New York
University of Rochester Medical Center
Rochester, New York
Atrium Health
Charlotte, North Carolina
Duke University Health System
Durham, North Carolina
Univ of Cincinnati Medical Center
Cincinnati, Ohio
The Ohio State University
Columbus, Ohio
Temple University
Philadelphia, Pennsylvania
AMR Knoxville
Knoxville, Tennessee
Austin Neuromuscular Center
Austin, Texas
Nerve and Muscle Center of Texas
Houston, Texas
University of Washington Medical Center
Seattle, Washington
Novartis Investigative Site
Southport, Australia
Novartis Investigative Site
North Ryde, New South Wales, Australia
Novartis Investigative Site
Herston, Queensland, Australia
Novartis Investigative Site
Caulfield South, Victoria, Australia
Novartis Investigative Site
Liège, Belgium
Novartis Investigative Site
Leuven, Vlaams Brabant, Belgium
Novartis Investigative Site
Calgary, Alberta, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Aalborg, Denmark
Novartis Investigative Site
Kobenhavn N V, Denmark
Novartis Investigative Site
Bron, France
Novartis Investigative Site
Lille, France
Novartis Investigative Site
Nice, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Tours, France
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Hanover, Germany
Novartis Investigative Site
Lübeck, Germany
Showing 40 of 74 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.